Genital herpes: antiviral therapy for symptom relief and prevention of transmission

Bibliography

• FLEMING D, MCQUILLAN G, JOHNSON R et al.: Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. (1997) 337(16):1105-1111.
   PubMed Web of Science ®Google Scholar
• LEONE P, FLEMING DT, GILSENAN AW, LI L, JUSTUS S: Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. Sex. Transm. Dis. (2004) 31(5):311-316.
   PubMed Web of Science ®Google Scholar
• WALD A, KOUTSKY L, ASHLEY R, COREY L: Genital herpes in a primary care clinic: demographic and sexual correlates of herpes simplex type 2 infection. Sex. Transm. Dis. (1997) 24:149-155.
   PubMedGoogle Scholar
• CHERPES TL, MEYN LA, KROHN MA, HILLIER SL: Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex. Transm. Dis. (2003) 30(5):405-410.
   PubMed Web of Science ®Google Scholar
• NAHMIAS A, LEE F, BECKMA-NAHMIAS S: Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J. Infect. Dis. (1990) 69:19-36.
   Google Scholar
• CROSBY RA, DICLEMENTE RJ, WINGOOD GM, ROSE E: Testing for HSV-2 infection among pregnant teens: implications for clinical practice. J. Pediatr. Adolesc. Gynecol. (2003) 16(1):39-41.
   PubMedGoogle Scholar
• GOTTLIEB SL, DOUGLAS JM Jr, SCHMID DS et al.: Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. J. Infect. Dis. (2002) 186(10):1381-1389.
   PubMed Web of Science ®Google Scholar
• AUSTIN H, MACALUSO M, NAHMIAS A et al.: Correlates of herpes simplex virus seroprevalence among women attending a sexually transmitted disease clinic. Sex. Transm. Dis. (1999) 26(6):329-334.
   PubMedGoogle Scholar
• KOUTSKY LA, ASHLEY RL, HOLMES KK et al.: The frequency of unrecognized type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex. Transm. Dis. (1990) 17:90-94.
   PubMed Web of Science ®Google Scholar
• MERTZ GJ, SCHMIDT O, JOURDEN JL et al.: Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex. Transm. Dis. (1985) 12:33-39.
   PubMed Web of Science ®Google Scholar
• COREY L, WALD A: Genital herpes (Ch. 21). In: Sexually Transmitted Diseases J Wasserheit (Ed.), McGraw-Hill, New York, NY, USA (1999):285-312.
   Google Scholar
• COREY L, WALD A, CELUM CL, QUINN TC: The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. (2004) 35(5):435-445.
   PubMed Web of Science ®Google Scholar
• COREY L, HOLMES KK: Genital herpes simplex virus infection: current concepts in diagnosis, therapy and prevention. Ann. Intern. Med. (1983) 98:973-983.
   PubMed Web of Science ®Google Scholar
• WALD A: New therapies and prevention strategies for genital herpes. Clin. Infect. Dis. (1999) 28:S4-S13.
   Google Scholar
• BRYSON YJ, DILLON M, LOVETT M et al.: Treatment of first episodes of genital herpes simplex virus infections with oral acyclovir: a randomized double-blind controlled trial in normal subjects. N. Engl. J. Med. (1983) 308:916-920.
   PubMed Web of Science ®Google Scholar
• MERTZ G, CRITCHLOW C, BENEDETTI J et al.: Double-blind placebo-controlled trial of oral acyclovir in the first episode genital herpes simplex virus infection. JAMA (1984) 252:1147-1151.
   PubMed Web of Science ®Google Scholar
• REITANO M, TYRING S, LANG W et al.: Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J. Infect. Dis. (1998) 178:603-610.
   PubMed Web of Science ®Google Scholar
• DIAZ-MITOMA F, SIBBALD RG, SHAFRAN SD et al.: Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. JAMA (1998) 280:887-892.
   PubMed Web of Science ®Google Scholar
• COREY L, WALD A, PATEL R et al.: Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. (2004) 350(1):11-20.
   PubMed Web of Science ®Google Scholar
• MINDEL A, WELLER I, FAHERTY A et al.: Acyclovir in first attacks of genital herpes and prevention of recurrences. Genitourin. Med. (1986) 62(1):28-32.
   PubMedGoogle Scholar
• FIFE KH, CRUMPACKER CS, MERTZ GJ et al.: Recurrence and resistance patterns of herpes simplex virus following cessation of > 6 years of chronic suppression with acyclovir. J. Infect. Dis. (1994) 169:1338-1341.
   PubMed Web of Science ®Google Scholar
• HAYDEN FG: Antimicrobial agents: antiviral agents. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. JG Hardman, LE Limbird, AG Goodman (Eds), McGraw-Hill, New York, NY, USA (2001):1313-1348.
   Google Scholar
• TYRING SK, BAKER D, SNOWDEN W: Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J. Infect. Dis. (2002) 186(Suppl. 1):S40-S46.
   PubMed Web of Science ®Google Scholar
• GOLDBERG LH, KAUFMAN R, KURTZ T et al.: Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. Arch. Dermatol. (1993) 129:582-587.
   PubMed Web of Science ®Google Scholar
• WALD A, BENEDETTI J, DAVIS G et al.: A randomized, double-blind, comparative trial comparing high and standard dose oral acyclovir for first-episode genital herpes infections. Antimicrob. Agents Chemother. (1994) 38:174-176.
   PubMedGoogle Scholar
• BELL W, CHULAY J, FEINBERG J: Manifestations resembling thrombotic microangiopathy in patients with advanced HIV disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (1997) 76:369-380.
   PubMed Web of Science ®Google Scholar
• SACKS S: Use of penciclovir and famciclovir in the management of genital herpes. Curr. Probl. Dermatol. (1996) 24:219-226.
   PubMedGoogle Scholar
• LOVELESS M, HARRIS W, SACKS S: Treatment of first episode genital herpes with famciclovir. Programmes and Abstracts of the 35th Interscience Conference on Antimicrob. Agents Chemother. San Francisco, CA, USA (1995).
   Google Scholar
• SCHACKER T, HU HL, KOELLE DM et al.: Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann. Intern. Med. (1998) 128(1):21-28.
   PubMed Web of Science ®Google Scholar
• CDC: Sexually transmitted disease treatment guidelines 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(RR-6):12-17.
   Google Scholar
• SACKS SL, AOKI FY, DIAZ-MITOMA F, SELLORS J, SHAFRAN SD: Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA (1996) 276:44-49.
   PubMed Web of Science ®Google Scholar
• ROMANOWSKI B, AOKI FY, MARTEL AY et al.: Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. Aids (2000) 14(9):1211-1217.
   PubMed Web of Science ®Google Scholar
• HENRY RE, WEGMANN JA, HARTLE JE, CHRISTOPHER GW: Successful oral acyclovir desensitization. Ann. Allergy (1993) 70(5):386-388.
   PubMedGoogle Scholar
• KAWSAR M, PARKIN JM, FORSTER G: Graded challenge in an aciclovir allergic patient. Sex. Transm. Infect. (2001) 77(3):204-205.
   PubMedGoogle Scholar
• SAFRIN S, CRUMPACKER C, CHATIS P et al.: A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N. Engl. J. Med. (1991) 325:551-555.
   PubMed Web of Science ®Google Scholar
• LALEZARI J, SCHACKER T, FEINBERG J et al.: A randomized, double-blind, placebo-controlled trial of cidofovir topical gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex infection in patients with AIDS. J. Infect. Dis. (1997) 176:892-898.
   PubMed Web of Science ®Google Scholar
• KESSLER H, HURWITZ S, FARTHING C et al.: Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1996) 12:147-152.
   PubMedGoogle Scholar
• MURPHY M, MORLEY A, EGLIN R, MONTEIRO E: Topical trifluridine for mucocutaneous acyclovir-resistant herpes simplex II in AIDS patient. Lancet (1992) 340:1040.
   PubMedGoogle Scholar
• KOUTSKY LA, STEVENS CE, HOLMES KK et al.: Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N. Engl. J. Med. (1992) 326:1539-1553.
   Google Scholar
• COREY L, ADAMS HG, BROWN ZA, HOLMES KK: Clinical course of genital herpes simplex virus infections in men and women. Ann. Intern. Med. (1983) 48:973.
   Google Scholar
• LAFFERTY WE, KROFFT S, REMINGTON M et al.: Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high prevalence population. J. Clin. Microbiol. (1987) 25:323-326.
   PubMed Web of Science ®Google Scholar
• RAMASWAMY M, MCDONALD C, SMITH M et al.: Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex. Transm. Infect. (2004) 80(5):406-410.
   PubMed Web of Science ®Google Scholar
• ASHLEY RL, WALD A: Genital herpes: review of the epidemic and potential use of type- specific serology. Clin. Microbiol. Rev. (1999) 12(1):1-8.
   PubMed Web of Science ®Google Scholar
• COREY L: Challenges in genital herpes simplex virus management. J. Infect. Dis. (2002) 186(Suppl. 1):S29-S33.
   Google Scholar
• GOLDEN MR, ASHLEY-MORROW R, SWENSON P, HOGREFE WR, HANDSFIELD HH, WALD A: HSV-2 western blot confirmatory testing among men testing positive for HSV-2 using the focus ELISA in an STD clinic. Sex. Transm. Dis. (2005) 32(12):771-777.
   PubMed Web of Science ®Google Scholar
• COREY L, BENEDETTI J, CRITCHLOW C et al.: Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. J. Antimicrob. Chemother. (1983) 12(Suppl. B):79-88.
   PubMedGoogle Scholar
• COREY L, FIFE KH, BENEDETTI JK et al.: Intravenous acyclovir for the treatment of primary genital herpes. Ann. Intern. Med. (1983) 98:914-921.
   PubMed Web of Science ®Google Scholar
• BRYSON YJ, DILLON M, LOVETT M et al.: Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N. Engl. J. Med. (1983) 308(16):916-921.
   PubMed Web of Science ®Google Scholar
• BENEDETTI JK, COREY L, ASHLEY R: Recurrence rates in genital herpes after symptomatic first-episode infection. Ann. Intern. Med. (1994) 121:847-854.
   PubMed Web of Science ®Google Scholar
• ENGELBERG R, CARRELL D, KRANTZ E, COREY L, WALD A: Natural history of genital herpes simplex virus type 1 infection. Sex. Transm. Dis. (2003) 30(2):174-177.
   PubMed Web of Science ®Google Scholar
• BODSWORTH NJ, CROOKS RJ, BORELLI S et al.: Valaciclovir versus acyclovir in patient-initiated treatment of recurrent genital herpes: a randomized, double-blind clinical trial. International Valaciclovir HSV Study Group. Genitourin. Med. (1997) 73:110-116.
   PubMedGoogle Scholar
• TYRING SK, DOUGLAS JM, COREY L, SPRUANCE SL, ESMANN J: A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. International Valaciclovir HSV Study Group. Arch. Dermatol. (1998) 134:185-191.
   PubMedGoogle Scholar
• CHOSIDOW O, DROUAULT Y, LECONTE-VEYRIAC F et al.: Famciclovir versus aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br. J. Dermatol. (2001) 144(4):818-824.
   PubMed Web of Science ®Google Scholar
• WALD A, CARRELL D, REMINGTON M et al.: Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin. Infect. Dis. (2002) 34(7):944-948.
   PubMed Web of Science ®Google Scholar
• STRAND A, PATEL R, WULF HC, COATES KM: Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex. Transm. Infect. (2002) 78(6):435-439.
   PubMed Web of Science ®Google Scholar
• AOKI FY, TYRING S, DIAZ-MITOMA F, GROSS G, GAO J, HAMED K: Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. (2006) 42(1):8-13.
   PubMed Web of Science ®Google Scholar
• PATEL R, TYRING S, STRAND A, PRICE MJ, GRANT DM: Impact of suppressive antiviral therapy on the health-related quality of life of patients with recurrent genital herpes infection. Sex. Transm. Infect. (1999) 75:398-402.
   PubMed Web of Science ®Google Scholar
• ROMANOWSKI B, MARINA RB, ROBERTS JN: Patients’ preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex. Transm. Dis. (2003) 30(3):226-231.
   PubMed Web of Science ®Google Scholar
• STRAUS S, TAKIFF H, SEIDLIN M et al.: Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. N. Engl. J. Med. (1984) 310:1545-1550.
   PubMed Web of Science ®Google Scholar
• DOUGLAS J, CRITCHLOW C, BENEDETTI J et al.: A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N. Engl. J. Med. (1984) 310:1551-1556.
   PubMed Web of Science ®Google Scholar
• MINDEL A, CARNEY O, FRERIS M et al.: Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet (1988) 1:926-928.
   PubMed Web of Science ®Google Scholar
• MERTZ GJ, LOVELESS MO, LEVIN MJ et al.: Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. Arch. Intern. Med. (1997) 157:343-349.
   PubMed Web of Science ®Google Scholar
• BENEDETTI JK, ZEH J, COREY L: Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann. Intern. Med. (1999) 131(1):14-20.
   PubMedGoogle Scholar
• PATRICK DM, ROSENTHAL SL, STANBERRY LR, HURST C, EBEL C: Patient satisfaction with care for genital herpes: insights from a global survey. Sex. Transm. Infect. (2004) 80(3):192-197.
   PubMedGoogle Scholar
• ALEXANDER L, NAISBETT B: Patient and physician partnerships in managing genital herpes. J. Infect. Dis. (2002) 186(Suppl. 1):S57-S65.
   PubMedGoogle Scholar
• WALD A, LANGENBERG A, LINK K et al.: Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA (2001) 285:3100-3106.
   PubMed Web of Science ®Google Scholar
• SMITH JS, ROBINSON NJ: Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. (2002) 186(Suppl. 1):S3-S28.
   PubMed Web of Science ®Google Scholar
• SIEGAL F, LOPEZ C, HAMMER G et al.: Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N. Engl. J. Med. (1981) 305:1439-1444.
   PubMed Web of Science ®Google Scholar
• SCHACKER T: The role of HSV in the transmission and progression of HIV. Herpes (2001) 8(2):46-49.
   PubMedGoogle Scholar
• AUGENBRAUN M, FELDMAN J, CHIRGWIN K et al.: Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann. Intern. Med. (1995) 123:845-847.
   PubMedGoogle Scholar
• SCHACKER T, ZEH J, HU HL, HILL J, COREY L: Frequency of symptomatic and asymptomatic HSV-2 reactivations among HIV-infected men. J. Infect. Dis. (1998) 178:1616-1622.
   PubMed Web of Science ®Google Scholar
• POSAVAD CM, WALD A, KUNTZ S et al.: Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J. Infect. Dis. (2004) 190(4):693-696.
   PubMedGoogle Scholar
• CONANT MA, SCHACKER TW, MURPHY RL et al.: Valaciclovir versus aciclovir for herpes simplex virus infection in HIV- infected individuals: two randomized trials. Int. J. STD AIDS (2002) 13(1):12-21.
   PubMed Web of Science ®Google Scholar
• GUPTA R, HILL EL, MCCLERNON D et al.: Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. J. Infect. Dis. (2005) 192(6):1102-1107.
   PubMedGoogle Scholar
• BACON TH, LEVIN MJ, LEARY JJ, SARISKY RT, SUTTON D: Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. (2003) 16(1):114-128.
   PubMed Web of Science ®Google Scholar
• SAFRIN S, ELBEIK T, PHAN L et al.: Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (1994) 38:1246-1250.
   PubMed Web of Science ®Google Scholar
• The Red Book: Phamacy’s Fundamental Reference. T Fleming (Ed.), Thomson Healthcare (2004):183, 346, 601.
   Google Scholar
• FIFE KH, BARBARASH RA, RUDOLPH T, DEGREGORIO B, ROTH R: Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind randomized clinical trial. Sex. Transm. Dis. (1997) 24:481-486.
   PubMed Web of Science ®Google Scholar
• SPRUANCE S, TRYING S, DEGREGORIO B et al.: A large-scale, placebo-controlled, dose-ranging trial of peroral valacyclovir for episodic treatment of recurrent herpes genitalis. Arch. Int. Med. (1996) 156:1729-1735.
   PubMed Web of Science ®Google Scholar
• SAIAG P, PRAINDHUI D, CHASTANG C: A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group. J. Antimicrob. Chemother. (1999) 44(4):525-531.
   PubMedGoogle Scholar